Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

NCT04889118 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib
DRUG: Placebo for lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]